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supports the assumption of a low-level neuroinflammatory 
process. Further support comes from the therapeutic benefit 
of anti-inflammatory medications in specific studies and the 
anti-inflammatory and immunomodulatory intrinsic effects 
of antipsychotics.  © 2014 S. Karger AG, Basel
 Introduction
 We humans are constantly being assaulted by infec-
tious agents, noxious chemicals and physical trauma. 
Fortunately, we have evolved a complex process – the in-
flammatory response – to help fight and clear infection, 
remove damaging chemicals and repair damaged tissue 
 [1] . The mechanisms underlying inflammation are of ma-
jor interest because, as noted by Hunter in 1794  [100] , 
‘when inflammation cannot accomplish that salutary 
purpose, it does mischief’. The harmful effects of inflam-
mation can be observed in many infectious or autoin-
flammatory diseases. The interactions between environ-
mental factors and genetically encoded components of 
the inflammatory response determine whether the result 
will be health or disease.
 As in other sites of the body, inflammation in the cen-
tral nervous system (CNS) has a dual role: it may be neu-
roprotective or neurotoxic  [2] . While acute inflammation 
in the CNS (e.g. acute encephalitis) leads to life-threaten-
ing states within hours or days, chronic inflammation in 
the CNS might be associated with impairment over 
months, years or a lifetime. 
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 Abstract
 Increased proinflammatory markers like cytokines have 
been described in the blood and cerebrospinal fluid of pa-
tients suffering from schizophrenia. Animal models have 
shown that a hit in early life to the immune system might 
trigger a lifelong increased immune reactivity. Many epide-
miological and clinical studies show the role of various infec-
tious agents as risk factors for schizophrenia with overlap to 
other psychoses. The first large-scale epidemiological study 
in psychiatry from Denmark clearly demonstrates severe in-
fections and autoimmune disorders during lifetime to be risk 
factors for schizophrenia. Genetic studies have shown the 
strongest signal for schizophrenia on chromosome 6p22.1, 
in a region related to the major histocompatibility complex 
and other immune functions. The vulnerability-stress-in-
flammation model is important as stress may increase proin-
flammatory cytokines and even contribute to a lasting pro-
inflammatory state. The immune system itself is considered 
an important further piece in the puzzle, as in autoimmune 
disorders in general, which are always linked to three factors: 
genes, the environment and the immune system. Alterations 
of dopaminergic, serotonergic, noradrenergic and glutama-
tergic neurotransmission have been shown with low-level 
neuroinflammation and may directly be involved in the gen-
eration of schizophrenic symptoms. Loss of central nervous 
system volume and microglial activation has been demon-
strated in schizophrenia in neuroimaging studies, which 
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 As an example, multiple sclerosis (MS) is an inflam-
matory disease of the CNS that shows a relapsing-remit-
ting course and, in a certain percentage of patients, also a 
chronic, progressive course. Parallels between MS and 
schizophrenia – both often show a chronic course – have 
repeatedly been highlighted as arguments for similar 
pathogenetic mechanisms in these disorders  [3] .
 The concept of ‘smoldering inflammation’ has been 
postulated for MS. It implies that CNS inflammation 
drives the disease process in both the chronic and acute 
stages  [4] . While there is a close interaction between the 
peripheral immune system and the CNS during acute in-
flammation, with invasion of macrophages, B and T cells 
into the latter, in chronic processes the immune response 
is thought to be increasingly secluded from the periph-
eral immune system (‘compartmentalization’ of the in-
flammatory process)  [5,  6] . Chronic MS, for example, is 
primarily characterized by disseminated activation of mi-
croglial cells.
 There are numerous descriptions of an association be-
tween chronic inflammation of the CNS and schizophre-
nia  [7] . For example, symptoms of schizophrenia have 
been described in the encephalitic form of MS  [8] , in viral 
CNS infection with herpes simplex virus types 1  [9] and 
2  [10] , and measles  [11] , and also in autoimmune pro-
cesses such as poststreptococcal disorders  [12–15] , lupus 
erythematodes and scleroderma  [16–19] . 
 Inflammatory Mechanisms in the CNS
 Inflammation in the CNS is mediated by proinflam-
matory cytokines, microglial cells (resident macrophages 
in the brain), astrocytes and invading immune cells such 
as monocytes, macrophages and T or B lymphocytes. Al-
though a well-regulated inflammatory process is essential 
for tissue homeostasis and proper function, an excessive 
inflammatory response can be the source of additional 
injury to host cells. Uncontrolled inflammation may be 
the result of either infectious agents (e.g. bacteria, viruses) 
or a secondary reaction to neuronal lesions from trauma, 
a genetic effect or environmental toxins.
 Microglia as an Important Cellular Basis of 
Inflammation in the CNS
 Microglia comprise approximately 15% of the total 
CNS cells and are the primary component of the intrinsic 
immune system in the CNS, where they provide the first 
line of defense after injury or disease and are the principal 
component of neuroinflammation.
 Microglia can be activated in different ways. One ex-
ample is when a systemic inflammatory challenge triggers 
microglia activation, resulting in the release of proinflam-
matory cytokines in the CNS, which can mediate ‘sick-
ness behavior’  [20] and other mental states. Microglia 
play a role in the synthesis of these central cytokines  [18] . 
Cytokine release can be sustained in the absence of the 
triggering signal for a period of about 10 months, and 
thus contribute to a chronic inflammatory state. Alterna-
tively, microglia are ‘sensitized’ or ‘primed’  [21] by differ-
ent stimuli, including neurodegeneration  [22] , ageing 
 [23] and stress  [24] . This process of sensitization or prim-
ing results in the elicitation of an exaggerated immune 
response to a low stimulus. After priming, a second stim-
ulus, e.g. low systemic inflammation or stress, may lead 
to microglia proliferation and increased production of 
proinflammatory cytokines by microglia  [25] . This exag-
gerated cytokine response may result in acute changes in 
behavior by exacerbating or re-exacerbating an inflam-
matory pathology in the CNS.
 Kindling and Sensitization of the Immune Response: 
Basis for the Stress-Induced Inflammatory Response 
in Psychiatric Disorders
 The immune response and the release of cytokines 
can become more sensitized for activating stimuli by a 
kindling process: the initial immune response, i.e. the 
release of cytokines and other mediators of immune ac-
tivation, is initiated as a result of exposure to a certain 
stimulus; thereafter, re-exposure to the same stimulus, 
e.g. stress or infection, is associated with an increased 
release of cytokines or a weaker stimulus is necessary for 
the same activation process. This ‘sensitization’ or ‘kin-
dling’ may be due to the memory function of the ac-
quired immune system  [24,  26] . Stress-associated re-
lease of interleukin (IL)-6 was shown to reactivate (pre-
natal) conditioned processes  [27] . In healthy individuals, 
a second stimulus (e.g. systemic inflammation, stress) 
led to immune activation associated with cellular prolif-
eration, and increased production and release of proin-
flammatory cytokines  [25] . This is a key mechanism for 
triggering an immune activation and inflammation, e.g. 
the stress-induced immune activation leading to psy-
chopathological symptoms. A sensitization process in 
the immune system is in accordance with the view that 
after an infection during early childhood, re-infection or 
another stimulation of the immune system in later stag-
es of life might be associated with a boosted release of 
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 Sensitization phenomena play a role in stress-related, 
cytokine-induced, neurotransmitter-mediated behavior-
al abnormalities, i.e. the cytokine response to a stimulus 
increases while the intensity of the stimulus decreases 
 [24] . In animal experiments, however, cytokines promote 
greater neurotransmitter responses when the animals are 
re-exposed to the cytokine  [28] , for example TNF-α  [29] . 
In the CNS, the stress-induced activation and prolifera-
tion of microglia may mediate these cytokine effects  [30] .
 The Vulnerability-Stress-Inflammation Model of 
Schizophrenia
 The vulnerability-stress model of psychiatric disor-
ders, first postulated for schizophrenia more than 30 
years ago  [31] , focuses on the role of physical and mental 
stress in triggering a psychotic episode. In schizophrenia 
an increased vulnerability of the offspring was shown – in 
addition to genetic vulnerability – if an inflammatory re-
sponse was induced in the mother during the second tri-
mester of pregnancy or in the offspring during later stag-
es of CNS development.
 The underlying mechanisms of the co-occurrence of 
stress and inflammation were studied in animal experi-
ments and stress was repeatedly shown to be associated 
with an increase in proinflammatory cytokines  [24] . The 
genetic risk contribution in the context of pathogen-host-
defense is evident  [32] .
 The specific influence of the inflammatory mecha-
nisms described in schizophrenia on neurotransmitter 
systems will be discussed below. Moreover, the modula-
tion of glutamatergic neurotransmission will be high-
lighted – glutamate is the most abundant neurotransmit-
ter in the CNS and is differentially involved via cytokine-
directed tryptophan/kynurenine metabolism in schizo - 
phrenia, presumably but not exclusively mediated by N-
methyl- D -asparate (NMDA) receptors. Beside others, ge-
netic factors of the kynurenine metabolites play a role 
 [33] .
 Inflammatory Markers in Schizophrenia
 Signs of inflammatory degradation products have 
been described in schizophrenic brain tissue  [34] – but 
not in control tissue – and in the cerebrospinal fluid 
(CSF) of about 50% of schizophrenic patients  [35] . Re-
garding the cytokine pattern in schizophrenia, a blunted 
type 1 and (compensatory) increased type 2 cytokine 
pattern has been repeatedly observed in unmedicated 
schizophrenic patients  [36] . Overviews on the imbal-
ance of the type 1 and type 2, and the pro- and anti-in-
flammatory immune systems, as well as the innate im-
munity, including the monocytic system, in schizophre-
nia have recently been published, revealing that an 
inflammatory process plays an important role in the 
pathophysiology of at least a subgroup of schizophrenic 
patients  [37,  38] . 
 The Impact of Inflammation on Neurotransmitters in 
Schizophrenia
 Over the last 5 decades, research on the neurobiology 
of schizophrenia has focused overwhelmingly on distur-
bances of dopaminergic neurotransmission  [39] . There is 
no doubt that a dysfunction of the dopamine system is 
involved in the pathogenesis of schizophrenia, although 
the mechanism is not clear and antipsychotic antidopa-
minergic drugs still show unsatisfactory therapeutic ef-
fects. 
 IL-1β, which can induce the conversion of rat mesen-
cephalic progenitor cells into a dopaminergic phenotype 
 [40–42] , and IL-6, which is highly effective in decreasing 
the survival of fetal brain serotonergic neurons  [43] , seem 
to have an important influence on the development of the 
neurotransmitter systems involved in schizophrenia, al-
though the specificity of these cytokines is a matter for 
discussion. Maternal immune stimulation during preg-
nancy was shown to increase the number of mesence-
phalic dopaminergic neurons in the fetal brain; the in-
crease was probably associated with a dopaminergic ex-
cess in the midbrain  [44] . Persistent pathogens might be 
key factors that drive imbalances of the immune reaction 
 [19] . Nevertheless, many questions about immunity and 
immune pathology in virus infections remain unan-
swered  [45] .
 Much evidence seems to indicate that a lack of gluta-
matergic neurotransmission, mediated via NMDA an-
tagonism, is a key mechanism in the pathophysiology of 
schizophrenia  [46] . The only NMDA receptor antago-
nist known to occur naturally in the human CNS is kyn-
urenic acid  [47] . Kynurenic acid is one of at least three 
neuroactive intermediate products of the kynurenine 
pathway. A predominant type 2 immune response in-
hibits the enzyme indoleamine 2,3-dioxygenase, result-
ing in an increased production of kynurenic acid in 
schizophrenia and in NMDA receptor antagonism  [46, 
48] . The recent findings of NMDA receptor antibodies 
in about 10% of acute diseased schizophrenia patients 
(unmedicated) is especially interesting in this regard 
 [49, 50] .
 Regarding the kynurenic acid in schizophrenia, how-
ever, discrepancies in the findings have to be discussed. 




















   
   
   
   
   
   
   
   
   
   
   


























CSF  [51, 52] and brains of schizophrenic patients  [53, 54] , 
or in animal models of schizophrenia  [55] . In the periph-
eral blood of first-episode schizophrenia  [56] and other 
samples of schizophrenic patients, no increased kynuren-
ic acid levels were observed  [57] . Antipsychotic medica-
tion, however, influences kynurenine metabolites and has 
to be regarded as an interfering variable  [56–58] .
 The Possible Role of Infection in Schizophrenia
 Animal models of schizophrenia show that stimula-
tion of the maternal immune system by viral agents 
leads to typical symptoms in the offspring  [59, 60] . Evi-
dence for pre- or perinatal exposure to infections as a 
risk factor for schizophrenia has not only been obtained 
from animal models  [61, 62] , studies in humans have 
also been performed on several viruses  [63–65] . In-
creased risk for schizophrenia in the offspring was also 
observed after respiratory infections  [66, 67] or genital 
or reproductive tract infections  [67, 68] . Infection of 
mothers with  Toxoplasma gondii  was also described to 
be a risk factor  [69] . 
 Infections before birth increase the risk for later schizo-
phrenia  [70–73] as well as infections – in particular CNS 
infections – during later stages of brain development. 
Nevertheless, antibody titers against viruses have been 
examined in the sera of schizophrenic patients for many 
years  [74] . The results, however, have been inconsistent, 
for example because interfering factors were not con-
trolled for. Antibody levels are associated with the medi-
cation state, a finding which partly explains earlier con-
troversial results  [75] . In one of our own studies, higher 
titers of different pathogens were found in schizophrenic 
patients than in controls, a phenomenon that we called 
the ‘infectious index’  [76] . 
 Prenatal immune activation – infection-triggered or 
not – is an important risk factor for schizophrenia  [60] . 
In humans, increased maternal levels of the proinflam-
matory cytokine IL-8 during pregnancy were shown to be 
associated with an increased risk for schizophrenia in the 
offspring, regardless of the reason for the increase in IL-8 
 [77] . Moreover, increased maternal IL-8 levels in preg-
nancy were also significantly related to decreased brain 
volume in the schizophrenic offspring, i.e. lower volumes 
of the right posterior cingulum and the left entorhinal 
cortex, and higher volumes of the ventricles  [78] .
 However, a recent study, the first large-scale epide-
miological study in psychiatry, showed that severe infec-
tions and autoimmune disorders during lifetime in-
crease additively the risk of schizophrenia and schizo-
phrenia spectrum disorders  [79] , whereas infections of 
the parents, including intrauterine infections, in this 
large-scale scenario were not confirmed as definite risk 
factors  [79, 80] . As the study sensitivity was evaluated as 
being not very high despite its large scale, only the ‘tip 
of an iceberg’ of risk factors may have been clearly iden-
tified  [80] .
 CNS Volume Loss in Imaging Studies – 
A Consequence of an Inflammatory Process?
 Gross inflammatory changes have not been found in 
neuroimaging or neuropathological studies of schizo-
phrenia. However, there is no doubt that a decreased CNS 
volume can already be observed during the first episode 
and a progressive loss in CNS volume occurs during the 
further course of the disease  [81–84] . Moreover, a rela-
tionship has been described between the volume loss and 
an increased genetic risk for a higher production of the 
immune marker IL-1β  [85] , whilst the relationship be-
tween maternal IL-8 levels and CNS volume has been 
mentioned before  [78] . 
 The PK11195 ligand is used in positron emission to-
mography, PET, to estimate microglial activation  [86] . In 
schizophrenia, the increased expression of PK11195 was 
shown to be a marker of an inflammatory process in the 
CNS  [87, 88] . Moreover, a positive correlation between 
schizophrenic-positive symptoms and expression of the 
PET-activation marker DAA1106, and of duration of dis-
ease and expression of the microglial activation marker 
DAA1106 was observed as well  [89] .
 Cyclo-Oxygenase-2 Inhibition as an
Anti-Inflammatory Therapeutic Approach in 
Schizophrenia
 Modern anti-inflammatory agents have been explored 
in schizophrenia. The cyclo-oxygenase-2 (COX-2) inhib-
itor celecoxib was studied in a prospective, randomized, 
double-blind study of acute exacerbation of schizophre-
nia. There was a statistically significant better outcome in 
the patients receiving celecoxib. The clinical effects of 
COX-2 inhibition in schizophrenia were especially pro-
nounced in cognition  [90] . The efficacy of therapy with a 
COX-2 inhibitor seems most pronounced in the first 
years of the schizophrenic disease process  [91, 92] . A re-
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salicylic acid in schizophrenic spectrum disorders  [93] . A 
meta-analysis of the clinical effects of nonsteroidal anti-
inflammatory drugs in schizophrenia revealed significant 
effects on schizophrenic total, positive and negative 
symptoms  [94] , while another meta-analysis found a sig-
nificant benefit only in schizophrenic patients with a 
short duration of disease or in first manifestation schizo-
phrenia  [95] .
 Regarding the role of microglia activation in inflam-
mation, minocycline, an inhibitor of microglia activation, 
is an interesting substance for the treatment of schizo-
phrenia. The improvement of cognition by minocycline 
has been described in animal models of schizophrenia 
 [96] , as well as in two double-blind, placebo-controlled 
add-on therapy trials in schizophrenia  [97,  98] . In clinical 
studies, positive effects on schizophrenic-negative symp-
toms were noted as well  [98] . Case reports have docu-
mented positive effects of minocycline on the whole 
symptom spectrum in schizophrenia  [99] .
 Conclusion 
 The possible influence of an immunological process 
for the pathogenesis of schizophrenia resulting in inflam-
mation has long been neglected. Increasing evidence for 
a role of proinflammatory cytokines in schizophrenia, the 
strong influence of pro- and anti-inflammatory cytokines 
on the tryptophan/kynurenine metabolism and, related 
to that mechanism, the influence of cytokines on the glu-
tamatergic neurotransmission, the results of imaging 
studies, genetic findings and, last but not least, the thera-
peutic effect of anti-inflammatory drugs support the view 
that psychoneuroimmunology and inflammation have 
rightly come more into the focus of schizophrenia re-
search. On the other hand, it has to be regarded that im-
munological research is susceptible to artefacts, interfer-
ing variables such as medication, smoking, stress, sleep 
and others play an important role and cannot always be 
controlled. This can be shown with the example of stress, 
which, according to the ‘vulnerability-stress model’, is 
not only a condition sine qua non in schizophrenia, but 
is also a confounding factor for research of the immune 
system and inflammatory processes. Similarly for neuro-
imaging studies, volume loss might be the result of differ-
ent pathological processes and factors other than inflam-
matory causes may play a role. Nevertheless, the results 
of these studies are encouraging and further studies 
should focus on the relationship between inflammatory 
markers in the blood, CSF and volume loss of the CNS. 
Moreover, the influence of different stages in schizophre-
nia might have been neglected, too. It is discussed that 
schizophrenia is a syndrome with different underlying 
pathological processes. Inflammation, however, also in-
cludes different stages and processes ranging from an 
acute to a chronic inflammation, including an autoim-
mune process.
 These considerations show that a lot of further re-
search is necessary to clarify the role of the immune sys-
tem in schizophrenia. However, recent results, including 
therapeutic progress, encourage further emphasis in this 
fascinating field.
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